The Biomarkers Consortium at the FNIH is the preeminent public-private partnership in qualifying biomarkers that accelerate therapeutic development and improve clinical care.

Join NIH, FDA, PhRMA, CMS, BIO and more than 40 companies and not-for-profit organizations in supporting the efforts of the Biomarkers Consortium. Large or small, public or private, established or growing, as a member your organization will benefit from active participation in the Biomarkers Consortium’s ongoing work.

Core activities of the Biomarkers Consortium are funded by membership dues from the private sector. Corporations, firms, advocacy groups, not-for-profit organizations, associations and philanthropic organizations interested in supporting biomarker development are eligible to become contributing members. Members elect representatives to serve on multi-stakeholder Steering Committees driving the work of the Biomarkers Consortium. Current Steering Committees are focused on developing projects in cancer, immunity and inflammation, metabolic disorders and neuroscience.

Membership Provides the Opportunity To:

  • Participate in identifying, selecting and developing new projects through the Biomarkers Consortium’s Steering Committees
  • Contribute directly to science that supports regulatory decision-making
  • Get an early window into opportunities to fund individual projects and participate in their execution as part of specific Project Teams
  • Take part in collaborative science with key opinion leaders and colleagues from a variety of research sectors and organizations
  • Participate directly in shaping opportunities to share data and resources in unique precompetitive research programs
  • Receive frequent updates on the status of the Biomarkers Consortium’s activities and new opportunities for involvement

 

ENTERPRISE MEMBERSHIP is for companies and organizations interested in participating on all Biomarkers Consortium Steering Committees (Cancer, Inflammation & Immunity, Metabolic Disorders, and Neuroscience). Members may:

  • Nominate qualified representatives to disease/therapeutic area-specific Steering Committees (all nominations to serve on Steering Committees are subject to approval by the co-chairs of each Steering Committee and ratification by the Executive Committee)
  • Be eligible for election to the Executive Committee that oversees and approves the Biomarkers Consortium’s work Consider first-tier opportunities to participate in selected projects as funding partners
  • Assist in the development of new projects by appointing a representative to serve on project Working Groups
  • Propose biomarker projects for execution by the Biomarkers Consortium Participate in Biomarkers Consortium communications and publicity activities

 

PER-COMMITTEE MEMBERSHIP is available to for-profit companies interested in joining select Biomarkers Consortium Steering Committees and, as relevant, have an annual research and development budget of at least $100 million. These members may nominate representatives for co-chair positions in chosen Steering Committee(s). Membership in at least two committees is required to nominate candidates, serve on and vote for Executive Committee positions.

MEMBERSHIP DUES
Membership is offered at several levels based on organization type and research and development budgets, if applicable within your industry. If you are interested in joining, download an application and contact development@fnih.org.

Front Page: